Cryosite dividend drought to end?, page-5

"...not much in the way of news for shareholders in this company."

Correct, @gmac55.  It's as if  management prefers to run this public company as a private company.  There's much happening in the clinical trials industry.  Cryosite could use its ASX platform to educate holders and others on developments and how they're affecting the company's prospects.  It would be good to see management apply energy and imagination to shareholder communication.

Meanwhile, the Cryosite continues to upgrade its website. The site now lists partnerships with three organizations: AusBiotech, ARCS Australia and Ecovadis.

It recently exhibited at the ARCS annual conference in Sydney. And furnished promotional lanyards for attendees.

CTE CEO John Hogg was a  program panelist. Alicia Steele, CTE Regulatory Affairs and Quality Assurance Manager, was a speaker. So there a welcome signs that - aside from the ASX -management is hoisting the group's industry profile.